DCOY

Decoy Therapeutics Inc. (DCOY) SWOT Analysis Analysis (2026)

Invetso Score: 3.9/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 4.8 (Moderate)

Negative cash conversion cycle of -56.9 days indicates suppliers and customers fund working capital, which is structurally better than peers with positive cycles.

Current and quick ratios of 1.83 suggest adequate near-term liquidity, reducing refinancing pressure relative to weaker balance-sheet peers.

Debt-to-equity of 0 and net debt to EBITDA of 0.57 indicate modest leverage, supporting financial flexibility versus more indebted competitors.

Weaknesses

Score:

ROIC of -3.4% shows capital is not earning its cost, leaving DCOY structurally behind profitable peers on value creation.

The absence of reported operating and gross margins limits transparency, but the negative ROIC implies weak underlying unit economics versus peers.

Liquidity is acceptable, yet it does not offset the low-return profile, so capital efficiency remains materially weaker than stronger peer operators.

Opportunities

Score:

If management converts the negative cash cycle into sustained free cash flow, DCOY could outperform peers that still absorb working capital.

Low leverage leaves room to fund operational improvements or selective growth without stressing the balance sheet, unlike more constrained peers.

Any margin normalization would have outsized impact because the current negative ROIC suggests even modest efficiency gains could narrow the peer gap.

Threats

Score:

Persistently negative ROIC threatens relative positioning because peers with positive returns can compound capital faster and widen the performance gap.

If working-capital dynamics reverse, DCOY could lose the cash-flow advantage that currently distinguishes it from peers with longer conversion cycles.

Limited margin disclosure increases uncertainty, and peers with clearer profitability trajectories may attract capital and customer confidence more easily.

Overall Score

Score:

DCOY’s structural positioning is weak versus peers because negative ROIC outweighs acceptable liquidity and modest leverage, despite a favorable cash conversion cycle.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Decoy Therapeutics Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →